Burd A, Levine RL, Shoben A, et al. Initial Report of the Beat AML Umbrella study for previously untreated AML: evidence of feasibility and early success in molecularly driven phase 1 and 2 studies. ASH Annual Meeting and Exposition 2018, abstract 559.
Rituximab of obinutuzumab of plus CHOP bij nieuw-gediagnostiseerd DLBCL
aug 2017 | Lymfoom